论文部分内容阅读
目的探讨厄贝沙坦治疗高血压性肾衰竭的临床疗效。方法选取盐亭县人民医院2014年10月—2016年5月收治的高血压性肾衰竭患者126例,按照随机数字表法将患者分为对照组与研究组,各63例。对照组予以硝苯地平及美托洛尔治疗,研究组在对照组基础上予以厄贝沙坦治疗。比较两组患者治疗前后收缩压、舒张压、血尿素氮、血肌酐及肾小球滤过率,观察不良反应发生情况。结果治疗前两组患者收缩压与舒张压比较,差异无统计学意义(P>0.05);治疗后研究组收缩压与舒张压低于对照组(P<0.05);治疗后两组收缩压与舒张压水平低于治疗前(P<0.05)。治疗前两组患者血尿素氮、血肌酐及肾小球滤过率比较,差异无统计学意义(P>0.05);治疗后研究组患者血尿素氮、血肌酐水平低于对照组,肾小球滤过率高于对照组(P<0.05);治疗后两组患者血尿素氮、血肌酐水平低于治疗前,肾小球滤过率高于治疗前(P<0.05)。两组患者均未发生严重不良反应。结论厄贝沙坦治疗高血压性肾衰竭的临床疗效确切,可有效降低患者血压,改善肾功能,且不良反应少。
Objective To investigate the clinical efficacy of irbesartan in the treatment of hypertensive renal failure. Methods Totally 126 hypertensive renal failure patients were selected from Yanting People’s Hospital from October 2014 to May 2016. The patients were divided into control group and study group according to the random number table method, with 63 cases in each group. The control group was treated with nifedipine and metoprolol, and the study group was treated with irbesartan on the basis of the control group. Systolic blood pressure, diastolic blood pressure, blood urea nitrogen, serum creatinine and glomerular filtration rate were compared between the two groups before and after treatment to observe the incidence of adverse reactions. Results Before treatment, systolic blood pressure and diastolic blood pressure were not significantly different between the two groups (P> 0.05). After treatment, systolic blood pressure and diastolic blood pressure in the study group were lower than those in the control group (P <0.05) Pressure levels were lower than before treatment (P <0.05). The blood urea nitrogen, serum creatinine and glomerular filtration rate in the two groups before treatment had no significant difference (P> 0.05). After treatment, the levels of blood urea nitrogen and serum creatinine in the study group were lower than those in the control group, The filtration rate of the ball was higher than that of the control group (P <0.05). After treatment, the levels of blood urea nitrogen and serum creatinine in both groups were lower than those before treatment, and glomerular filtration rate was higher than before treatment (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Irbesartan in the treatment of hypertensive renal failure, the exact clinical efficacy, can effectively reduce the patient’s blood pressure, improve renal function, and less adverse reactions.